Covered recipient · General Payments record
STEVEN J PRICE
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2018–2024
$1,543.44
- Reported across 77 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $284.91 | 14 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| SK Life Science, Inc. | $45.59 | 2 |
| Kyowa Kirin, Inc. | $45.35 | 2 |
| Genentech USA, Inc. | $35.34 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $23.34 | 1 |
| UCB, Inc. | $22.83 | 1 |
| ARGENX US, INC. | $22.64 | 1 |
| Amneal Pharmaceuticals LLC | $19.87 | 1 |
| EISAI INC. | $19.67 | 1 |
| Medtronic, Inc. | $18.10 | 1 |
| Acorda Therapeutics, Inc | $17.98 | 1 |
| PFIZER INC. | $14.20 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (14)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Acorda Therapeutics, Inc | $17.98 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142350062 | CMS |
| Amneal Pharmaceuticals LLC | $19.87 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139198574 | CMS |
| ARGENX US, INC. | $22.64 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142113267 | CMS |
| Eisai Inc. | $19.67 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110783208 | CMS |
| Genentech USA, Inc. | $18.24 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133117905 | CMS |
| Genentech USA, Inc. | $17.10 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133117902 | CMS |
| Kyowa Kirin, Inc. | $20.38 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127043739 | CMS |
| Kyowa Kirin, Inc. | $24.97 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127043741 | CMS |
| Medtronic, Inc. | $18.10 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119325113 | CMS |
| Novartis Pharmaceuticals Corporation | $23.34 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087320267 | CMS |
| PFIZER INC. | $14.20 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130990879 | CMS |
| SK Life Science, Inc. | $23.22 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154150596 | CMS |
| SK Life Science, Inc. | $22.37 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154150616 | CMS |
| UCB, Inc. | $22.83 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143329685 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.